Novavax Stock Soars On FDA COVID-19 Update: Fundamental Rally Or Potential Short Squeeze?

Novavax, Inc. NVAX is back in the spotlight as its stock skyrockets following a wave of positive news about its COVID-19 vaccine.

The FDA has notified Novavax that it completed the filing review of the final portion of its Biologics License Application for its COVID-19 vaccine, setting a PDUFA review goal date for April 2025.

This update comes just as an FDA advisory committee voted to recommend updated vaccines for the JN.1-lineage composition. Novavax expects to be ready for delivery by September, pending authorization.

More on the Novavax buzz, here: Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September

Novavax Stock Experiencing High Trading Volume

This news has propelled Novavax shares higher, with the stock trading up more than 300% over the past month and nearly 40% in the past five days.

Vaccine makers, including Novavax, reported data from animal studies showing that shots targeting the JN.1 variant could neutralize newer subvariants more effectively than older shots. With the FDA advising that COVID-19 vaccine makers target the JN.1 and KP.2 subvariants for the 2024-2025 campaign, Novavax is well-positioned to meet this demand.

The excitement around Novavax’s COVID-19 vaccine isn’t just due to regulatory milestones, high trading volume has been another significant factor in Novavax’s recent stock performance.

Over 30.7 million shares were traded on Wednesday, and 36.47% of shares are being sold short.

This high short-interest can lead to outsized price movements when combined with heavy trading volume. With 2.5 days to cover, investors wonder whether the rally is fundamentally driven or the stock is experiencing a short squeeze.

Key Indicators Point To A Strong Bullish Trend

Chart: Benzinga Pro

For investors, the technical indicators are promising. Novavax’s stock is trading above its 5, 20, and 50-day exponential moving averages, signaling a strong bullish trend. The Relative Strength Index (RSI) at 87.41 suggests that the stock is overbought, but the overall sentiment remains positive.

Despite the company’s past volatility and speculative nature, Novavax’s recent developments, including its involvement in the COVID-19 vaccine updates and strong market performance, position it as a compelling investment for those looking to capitalize on the next big wave in biotech.

Investors should keep a close eye on Novavax as it navigates these exciting opportunities.

Read Next: What’s Going On With Novavax Stock?

Image generated using artificial intelligence via Midjourney.